1. Home
  2. ATIIW vs SRPT Comparison

ATIIW vs SRPT Comparison

Compare ATIIW & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATIIW
  • SRPT
  • Stock Information
  • Founded
  • ATIIW N/A
  • SRPT 1980
  • Country
  • ATIIW United States
  • SRPT United States
  • Employees
  • ATIIW N/A
  • SRPT N/A
  • Industry
  • ATIIW Blank Checks
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATIIW Finance
  • SRPT Health Care
  • Exchange
  • ATIIW Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • ATIIW N/A
  • SRPT N/A
  • IPO Year
  • ATIIW 2025
  • SRPT 1997
  • Fundamental
  • Price
  • ATIIW $0.26
  • SRPT $37.60
  • Analyst Decision
  • ATIIW
  • SRPT Buy
  • Analyst Count
  • ATIIW 0
  • SRPT 23
  • Target Price
  • ATIIW N/A
  • SRPT $125.43
  • AVG Volume (30 Days)
  • ATIIW N/A
  • SRPT 5.9M
  • Earning Date
  • ATIIW N/A
  • SRPT 05-06-2025
  • Dividend Yield
  • ATIIW N/A
  • SRPT N/A
  • EPS Growth
  • ATIIW N/A
  • SRPT N/A
  • EPS
  • ATIIW N/A
  • SRPT N/A
  • Revenue
  • ATIIW N/A
  • SRPT $2,233,371,000.00
  • Revenue This Year
  • ATIIW N/A
  • SRPT $39.01
  • Revenue Next Year
  • ATIIW N/A
  • SRPT $13.35
  • P/E Ratio
  • ATIIW N/A
  • SRPT N/A
  • Revenue Growth
  • ATIIW N/A
  • SRPT 59.15
  • 52 Week Low
  • ATIIW N/A
  • SRPT $34.10
  • 52 Week High
  • ATIIW N/A
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • ATIIW N/A
  • SRPT 33.31
  • Support Level
  • ATIIW N/A
  • SRPT $36.89
  • Resistance Level
  • ATIIW N/A
  • SRPT $39.56
  • Average True Range (ATR)
  • ATIIW 0.00
  • SRPT 2.14
  • MACD
  • ATIIW 0.00
  • SRPT 0.95
  • Stochastic Oscillator
  • ATIIW 0.00
  • SRPT 34.86

About ATIIW Archimedes Tech SPAC Partners II Co. Warrant

Archimedes Tech SPAC Partners II Co is a blank check company.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: